Prognostic significance of Tryptophan catabolism in adult t-cell leukemia/lymphoma

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2830-2839

  Masaki, Ayako ^a   Ishida, Takashi ^a   Maeda, Yasuhiro ^b   Suzuki, Susumu ^c   Ito, Asahi ^a   Takino, Hisashi ^a   Ogura, Hiroka ^a   Totani, Haruhito ^a   Yoshida, Takashi ^a   Kinoshita, Shiori ^a   Narita, Tomoko ^a   Ri, Masaki ^a   Kusumoto, Shigeru ^a   Inagaki, Atsushi ^d   Komatsu, Hirokazu ^a   Niimi, Akio ^a   Ueda, Ryuzo ^c   Utsunomiya, Atae ^e   Inagaki, Hiroshi ^a   Iida, Shinsuke ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b Nagoya City University   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Nagoya City University West Medical Center   (Japan)

^e IMAMURA BUN IN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN; BIOLOGICAL MARKER;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ASYMPTOMATIC INFECTION; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; T CELL LEUKEMIA; TRYPTOPHAN METABOLISM; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; KYNURENINE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPH NODES; MALE; MIDDLE AGED; PROGNOSIS; TRYPTOPHAN;

EID: 84941953178     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2275     Document Type: Article

References (50)

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481-92.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980;77:7415-9.
3. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981; 78:6476-80.
4. ShimoyamaM. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984-1987). Br J Haematol 1991;79:428-37.
5. Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, HarringtonW Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 2009;27:453-9.
6. Ishida T, Ueda R. Antibody therapy for adult T-cell leukemialymphoma. Int J Hematol 2011;94:443-52.
7. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007;7:70-280.
8. Suzuki S, Masaki A, Ishida T, Ito A, Mori F, Sato F, et al. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. Cancer Sci 2012;103:1764-73.
9. Masaki A, Ishida T, Suzuki S, Ito A, Mori F, Sato F, et al. Autologous Taxspecific CTL therapy in a primary ATL cell-bearing NOD/Shi-scid, IL-2Rgnull mouse model. J Immunol 2013;191:135-44.
10. Arnulf B, ThorelM, Poirot Y, Tamouza R, Boulanger E, Jaccard A, et al. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 2004;18:126-32.
11. Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, et al. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood 2012;119:3097-104.
12. Narita T, Ishida T, Masaki A, Suzuki S, Ito A, Mori F, et al. HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation. J Immunol 2014;192:940-7.
13. Itonaga H, Tsushima H, Taguchi J, Fukushima T, Taniguchi H, Sato S, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki Transplant Group experience. Blood 2013;121:219-25.
14. Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, et al. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study. Biol Blood Marrow Transplant 2013;19:1731-9.
15. Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007;120:2052-7.
16. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011;102:44-50.
17. Mori N, Gill PS, Mougdil T, Murakami S, Eto S, Prager D. Interleukin-10 gene expression in adult T-cell leukemia. Blood 1996;88:1035-45.
18. Kim SJ, Kehrl JH, Burton J, Tendler CL, Jeang KT, Danielpour D, et al. Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: A potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia. J Exp Med 1990;172:121-9.
19. Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, et al. Clinical significance of serum Th1-, Th2-And regulatory T cells-Associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and-10 levels are significant unfavorable prognostic factors. Int J Cancer 2006;118:3054-61.
20. Löb S, Königsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2, 3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009;9:445-52.
21. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72:5435-40.
22. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011;17:6985-91.
23. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014;28:1784-92.
24. Hoshi M, Ito H, Fujigaki H, Takemura M, Takahashi T, Tomita E, et al. Indoleamine 2, 3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity. Leuk Res 2009;33:39-45.
25. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, TaraM, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult Tcell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001;113:375-82.
26. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007;25:5458-64.
27. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16:1520-31.
28. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. JClin Oncol 2012;30:837-42.
29. Maeda Y, Ito T, Ohmi H, Yokoi K, Nakajima Y, Ueta A, et al. Determination of 3-hydroxyisovalerylcarnitine and other acylcarnitine levels using liquid chromatography-Tandem mass spectrometry in serum and urine of a patient with multiple carboxylase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci 2008;870:154-9.
30. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, et al. Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008;14:2310-7.
31. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003;9:3625-34.
32. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-6.
33. Sperner-Unterweger B, Neurauter G, KlieberM, Kurz K, Meraner V, Zeimet A, et al. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology 2011;216:296-301.
34. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, et al. Tryptophan 2, 3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2009;2:8.
35. SchutzG, ChowE, Feigelson P. Regulatory properties of hepatic tryptophan oxygenase. J Biol Chem 1972;247:5333-7.
36. Utsunomiya A, Ishida T, Inagaki A, Ishii T, Yano H, Komatsu H, et al. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: A blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res 2007;31:915-20.
37. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute-And lymphoma-Type adult T-cell leukemia/lymphoma. J Clin Oncol 2012;30:1635-40.
38. Umino A, Nakagawa M, Utsunomiya A, Tsukasaki K, Taira N, Katayama N, et al. Clonal evolution of adult T-cell leukemia/lymphoma takes place in the lymph nodes. Blood 2011;117:5473-8.
39. Suguro M, Yoshida N, Umino A, Kato H, Tagawa H, Nakagawa M, et al. Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis. Cancer Sci 2014;105:897-904.
40. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-72.
41. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002;107:452-60.
42. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002;196:459-68.
43. Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196:447-57.
44. Fallarino F, Grohmann U, Vacca C, Orabona C, Spreca A, Fioretti MC, et al. T cell apoptosis by kynurenines. Adv Exp Med Biol 2003;527:183-90.
45. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203.
46. Hayashibara T, Yamada Y, Mori N, Harasawa H, Sugahara K, Miyanishi T, et al. Possible involvement of aryl hydrocarbon receptor (AhR) in adult Tcell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 2003;300:128-34.
47. Sørensen RB, Køllgaard T, Andersen RS, van den Berg JH, Svane IM, Straten Pt, et al. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2, 3-dioxygenase-2. Cancer Res 2011;71:2038-44.
48. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: A novel, active target. J Am Coll Surg 2009;208:781-7.
49. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase. Proc Natl Acad Sci U S A 2012;109:2497-502
50. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010;115:3520-30